DelistingJul 31, 2026, 05:21 PM
bioAffinity Technologies Receives Nasdaq Delisting Notice
AI Summary
bioAffinity Technologies, Inc. received a notice from Nasdaq on July 30, 2026, indicating non-compliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive business days. The company is not eligible for the standard 180-day compliance period due to a 1-for-30 reverse stock split effected on September 19, 2025. bioAffinity Technologies plans to appeal the determination to Nasdaq on August 6, 2026, which will temporarily halt the delisting process.
Key Highlights
- Received Nasdaq delisting notice on July 30, 2026, for non-compliance.
- Bid price closed below $1.00 per share for 30 consecutive business days.
- Not eligible for 180-day compliance period due to prior reverse stock split.
- Effected a 1-for-30 reverse stock split on September 19, 2025.
- Company intends to appeal to Nasdaq on August 6, 2026.
- Appeal will stay delisting and suspension of securities pending Panel decision.
Price Impact
More from BIAF